Biotech | March 16, 2022
Sanofi announces €300 million collaboration with Blackstone Life Sciences
The investment will accelerate the overall Sarclisa development program
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
The expansion is part of Lonza’s continued investment in its global manufacturing network, aiming to build a comprehensive offering for global customers
Subscribe To Our Newsletter & Stay Updated
